Patent foramen ovale medical therapy: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
== | =='''Internatioanl guidelines for prevention of recurrent cerebral embolism in patent foramen ovale '''== | ||
==American Academy of Neurology Guidelines for prevention of recurrent cerebral embolism in patent foramen ovale (DO NOT EDIT)<ref name="pmid15078999">{{cite journal| author=Messé SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G et al.| title=Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. | journal=Neurology | year= 2004 | volume= 62 | issue= 7 | pages= 1042-50 | pmid=15078999 | doi= | pmc= | url= }} </ref>== | |||
{{cquote| | |||
'''Practice Recommendations''' | |||
'''1)''' For patients who have had a [[Paradoxical embolism|cryptogenic stroke]] and have a [[patent foramen ovale]] ([[PFO]]), the evidence indicates that the risk of subsequent [[stroke]] or death is no different from other [[Paradoxical embolism|cryptogenic stroke]] patients without [[PFO]] when treated medically with [[antiplatelet]] agents or [[anticoagulant]]s. Therefore, in persons with a [[Paradoxical embolism|cryptogenic stroke]] receiving such therapy, neurologists should communicate to patients and their families that presence of [[PFO]] does not confer an increased risk for subsequent [[stroke]] compared to other [[Paradoxical embolism|cryptogenic stroke]] patients without atrial abnormalities '''(Level A)'''. However, it is possible that the combination of [[PFO]] and atrial septal aneurysm (ASA) confers an increased risk of subsequent [[stroke]] in medically treated patients who are less than 55 years of age. Therefore, in younger [[stroke]] patients, studies that can identify [[PFO]] or atrial septal aneurysm (ASA) may be considered for prognostic purposes '''(Level C)'''. | |||
'''2)''' Among patients with a [[Paradoxical embolism|cryptogenic stroke]] and atrial septal abnormalities, there is insufficient evidence to determine the superiority of [[aspirin]] or [[warfarin]] for prevention of recurrent [[stroke]] or death '''(Level U)''', but the risks of minor [[bleeding]] are possibly greater with [[warfarin]] '''(Level C)''' | |||
}} | |||
==References== | ==References== | ||
Revision as of 23:43, 5 September 2011
|
Patent Foramen Ovale Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Patent foramen ovale medical therapy On the Web |
|
American Roentgen Ray Society Images of Patent foramen ovale medical therapy |
|
Risk calculators and risk factors for Patent foramen ovale medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [3]
Overview
Internatioanl guidelines for prevention of recurrent cerebral embolism in patent foramen ovale
American Academy of Neurology Guidelines for prevention of recurrent cerebral embolism in patent foramen ovale (DO NOT EDIT)[1]
| “ |
Practice Recommendations 1) For patients who have had a cryptogenic stroke and have a patent foramen ovale (PFO), the evidence indicates that the risk of subsequent stroke or death is no different from other cryptogenic stroke patients without PFO when treated medically with antiplatelet agents or anticoagulants. Therefore, in persons with a cryptogenic stroke receiving such therapy, neurologists should communicate to patients and their families that presence of PFO does not confer an increased risk for subsequent stroke compared to other cryptogenic stroke patients without atrial abnormalities (Level A). However, it is possible that the combination of PFO and atrial septal aneurysm (ASA) confers an increased risk of subsequent stroke in medically treated patients who are less than 55 years of age. Therefore, in younger stroke patients, studies that can identify PFO or atrial septal aneurysm (ASA) may be considered for prognostic purposes (Level C). 2) Among patients with a cryptogenic stroke and atrial septal abnormalities, there is insufficient evidence to determine the superiority of aspirin or warfarin for prevention of recurrent stroke or death (Level U), but the risks of minor bleeding are possibly greater with warfarin (Level C)
|
” |